RNAC Stock Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
RNAC stock results show that Cartesian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
The post RNAC Stock Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace.
More From InvestorPlace